TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00573937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
Study: NCT00381641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT00689780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1940
Description: Oral solution Multiple ascending dose given orally once daily at day 1-12

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Oral solution given orally once daily on day -1 and day 14
Study: NCT04051281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
Study: NCT01127035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sublingual immunotherapy

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03898258

Intervention type: OTHER
Intervention: Qualiveen full version
Description: Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
Study: NCT01548391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX-1171
Description: 20mg, 200mg, 500mg
Study: NCT03898258

Intervention type: OTHER
Intervention: Qualiveen short-form
Description: Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
Study: NCT03567577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solnatide 25 mg powder for reconstitution for solution for inhalation
Description: Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solnatide 25 mg powder for reconstitution for solution for inhalation
Description: Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
Study: NCT01614769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Description: One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
Study: NCT03567577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solnatide 25 mg powder for reconstitution for solution for inhalation
Description: Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Description: Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
Study: NCT04204837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Relatlimab
Description: Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit
Study: NCT01614769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Description: One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Description: One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
Study: NCT02387138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G-csf
Description: G-csf : d8 to d13 systematically
Study: NCT00809354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg every 8 weeks (through Week 48)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg every 8 weeks (through Week 48)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID
Description: Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
Study: NCT02213640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control: placebo stimulation
Description: electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
Study: NCT01614769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Description: One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
Study: NCT04701710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin / Iota-Carrageenan
Description: The EG received Ivermectin orally 2 drops of 6 mg = 12 mg every 7 days, and Iota-Carrageenan 6 sprays per day for 4 weeks.
Study: NCT01701921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Pregabalin 75mg by mouth one hour before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin 150 mg
Description: pregabalin 150mg by mouth one hour before surgery
Study: NCT03420820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacterial Culture Swab
Description: Culture swabs will be obtained before application of PI and after injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacterial Culture Swab
Description: Culture swabs will be obtained before application of PI and after injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacterial Culture Swab
Description: Culture swabs will be obtained before application of PI and after injection.
Study: NCT01701921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
Study: NCT01614769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Description: One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Description: One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Description: Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
Study: NCT00618787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COPA AMD (note: name is not an acronym)
Description: Foam dressing impregnated with Polyhexamethylene Biguanide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COPA (note: name is not an acronym)
Description: Regular foam dressing without PHMB
Study: NCT03436667

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: Lung volumes will be measured using spirometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Reaction Time
Description: PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
Study: NCT04194242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC96719 tablets
Description: 0.1、0.2、0.5、1、2、3、4 mg HEC96719 tablet in day1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 0.1、0.2、0.5、1、2、3、4 mg Placebo tablet in day1
Study: NCT02760342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peficitinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral
Study: NCT00813020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
Study: NCT04348643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: CEA-CAR-T cells will be administered intravenously.
Study: NCT00254761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Study: NCT04486716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml)
Study: NCT01614769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Description: Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
Study: NCT00254761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Study: NCT00693849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg/day as a single dose, increased to max 20 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 50 mg/day as a single dose, increased to max of 200 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine-XR
Description: 75 mg/day given once daily; increased to 150-225 mg/day
Study: NCT03493620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device arm
Description: Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham arm
Description: Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
Study: NCT01614769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Description: Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Description: Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Description: Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Description: Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Clamp
Description: On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Clamp
Description: On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Clamp
Description: On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Clamp
Description: On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Clamp
Description: On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypoglycemic Clamp
Description: On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
Study: NCT01806077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ-128
Description: Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
Study: NCT03727321

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant
Description: Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
Study: NCT02505295

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 4 vials selenase stat and 2 vials daily for 5 days
Study: NCT04129398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir tablet
Description: A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir IV
Description: IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
Study: NCT04366310

Intervention type: DEVICE
Intervention: capillary refill index
Description: a waveform analysis method using a pulse oximeter to assess peripheral perfusion

Intervention type: PROCEDURE
Intervention: rewarming
Description: warming fingertip skin temperature using an instant hot pack
Study: NCT02505295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal saline infusion like intervention group
Study: NCT03727321

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant
Description: Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: A combination of soluble corn fiber (PROMITOR®: Tate\&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cellulose
Description: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
Study: NCT03434574

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia extract
Description: Powdered extract obtained from aronia berries (Aronia melanocarpa).
Study: NCT03727321

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
Study: NCT04307147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine (at a dose of 1250 mg/m², twice per day, on days 1 to 14) every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Intravenous vinorelbine (at a dose of 25 mg/m² on day 1, day 8) every 3 weeks for 4 cycles.
Study: NCT03437772

Intervention type: BEHAVIORAL
Intervention: Mindfulness Cognitive Behavioral Therapy program
Description: 16 simultaneous-but-separate therapy sessions for parents and children.
Study: NCT03272334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 BATs with Pembrolizumab
Description: 8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 BATs with Pembrolizumab
Description: 8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 BATs with Pembrolizumab
Description: 8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
Study: NCT02953431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP will be administered with a CPAP machine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Description: CPAP will be administered with a CPAP machine
Study: NCT03286868

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty with Verasense sensor
Description: Total Knee Arthroplasty with Verasense sensor
Study: NCT00936936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1800 mg/m\^2 IV over 3 hours on Days -5 to Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 300 mg/m\^2 IV over 2 hours on Day -5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 mg/m\^2 IV over 15 minutes on Days -4 to Day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Cycle 1: 333 mg/m\^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m\^2 IV over 2 hours on Days -6 to -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 3,000 mg/m\^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3,000 mg/m\^2 IV over 6 hours on Days -6 to -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m\^2 IV over 3 hours, every 12 hours on Days -6 to -4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.
Study: NCT00499447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy